Amlodipine/atorvastatin
 | |
 | |
| Combination of | |
|---|---|
| Amlodipine | Calcium channel blocker |
| Atorvastatin | Statin |
| Clinical data | |
| Trade names | Caduet, Envacar |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| (verify) | |
The drug combination atorvastatin/amlodipine (brand names Caduet in the United States, Australia, and Russia; and Envacar elsewhere) is a medication approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol and high blood pressure. It is a fixed-dose combination drug containing a HMG-CoA reductase inhibitor and a calcium channel blocker being marketed by the pharmaceutical company Pfizer.[1][2]
References
- ^ "CADUET (amlodipine besylate/atorvastatin calcium) Tablets" (PDF). NDA 21-540/S-009. United States Food and Drug Administration. February 2010. Retrieved 2010-09-25.
- ^ Devabhaktuni M, Bangalore S (2009). "Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives". Vascular Health and Risk Management. 5 (1): 377–87. doi:10.2147/vhrm.s3339. PMC 2686256. PMID 19475775.
{{cite journal}}: CS1 maint: unflagged free DOI (link)
External links
- "Amlodipine Besylate mixture with Atorvastatin Calcium". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |